Crystal forms of (6 - 4 - (piperazin-1-yl Ethyl methyl) phenyl - 7h pyrrolo 2, 3-d pyrimidin-4-yl) - (R) - 1 - phenyl Ethyl Amine and the same in Amorphous State, Preparation methods the same, Pharmaceutical compositions containing them and the use of these forms Crist

摘要

Crystal forms of (6 - [4 - (ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3-d] pyrimidine II} - (4 - (R) - 1 - phenyl ethyl) Amine, the procedure for the preparation of these Crystalline forms of {6 - [4 - (ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3-d] pyrimidine II} - (4 - (R) - 1 - phenyl ethyl) amine.Compositions containing the Crystalline forms (6 - [4 - (ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3-d] pyrimidine II} - (4 - (R) - 1 - phenyl ethyl) Amine, and the use of these Crystalline forms {6 - [4 - (ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3-d] pyrimidine II} - (4 - (R) - 1 - phenyl ethyl) amine In the therapy of warm blooded Animals, especially humans.Claim 2: The Compound according to claim 1, which shows a diffraction Peak of x ray diffraction Angle 2 Theta 4.4u00b0 + - 0.2 degrees (%).Claim 1, a process for the preparation of Crystalline form of {6 - [4 - (ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3-d] pyrimidin-4-yl) - ((R) - 1 - phenyl ethyl) Amine which includes: (a) contacting {6 - [4 - (Ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3 - d] pyrimidin-4-yl) - ((R) - 1 - phenyl ethyl) Amine with a Solvent to form a precipitate; (b) to resuspend the pellet in a Second Solvent to form a Second precipitate; and (c) separating the second precipitate. Claim 1: The Compound according to claim 1, which shows a diffraction Peak of x-ray diffraction Angle 2 Theta 5.7u00b0 + - 0.2u00b0.Claim 31: a process for the preparation of Crystalline Form b {6 - [4 - (ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3-d] pyrimidine II} - (4 - (R) - 1 - phenyl ethyl) Amine which includes: (a) contacting {6 - [4 - (ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3 - d] pyrimidin-4-yl) - ((R) - 1 - phenyl ethyl) Amine with a Solvent to form a precipitate; and (b) separating the second precipitate. The Compound claim 35: According to claim 25, which shows a diffraction Peak of x-ray diffraction Angle 2 Theta 5.7u00b0 + - 0.2u00b0.Claim 47: a process for the preparation of Crystalline form c {6 - [4 - (ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3-d] pyrimidin-4-yl) - ((R) - 1 - phenyl ethyl) Amine which includes: (a) contacting {6 - [4 - (Ethyl - piperazin - 1 - methyl) phenyl] - 7h pyrrolo [2,3 - d] pyrimidin-4-yl) - ((R) - 1 - phenyl ethyl) Amine with a Solvent to form a precipitate; and (b) separating the second precipitate. The Compound claim 52: According to claim 51, which has substantially the same x-ray diffraction pattern as shown in Figure 11.